LOGIN  |  REGISTER
Assertio

LifeMD to Participate in Upcoming Investor Conferences and Webinar

February 15, 2024 | Last Trade: US$8.26 0.10 1.23

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced that management will be participating in three upcoming investor conferences and a webinar discussing GLP-1s.

  • D.A. Davidson GLP-1 Webinar, February 26, 2024. Justin Schreiber, Chief Executive Officer of LifeMD, will participate in a webinar with equity research analysts Gil Luria and Linda Bolton Weiser to discuss his perspective on GLP-1s.

  • TD Cowen’s 44th Annual Health Care Conference, March 4-6, 2024 at the Boston Marriott Copley Place. Management will be presenting a corporate overview and will be holding one-on-one meetings with investors.

  • Oppenheimer 34th Annual Healthcare MedTech & Services Conference, March 12-13, 2024. Management will deliver a virtual company presentation and will hold one-on-one virtual meetings with investors.

  • KeyBanc Capital Markets Life Sciences & MedTech Investor Forum: Virtual, March 19-20, 2024. Management will be participating in a virtual fireside chat and will be holding one-on-one virtual meetings with investors.

About LifeMD, Inc.

LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s health, women’s health, allergy & asthma, and dermatology. The Company leverages a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient care center to increase access to top-notch and affordable care. For more information, please visit LifeMD.com.

Investor Contact
Marc Benathen, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Jessica Friedeman, Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page